Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04991532 alone · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-04991532 alone | EXPERIMENTAL | - |
| PF-04991532 + cyclosporine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04991532 alone | DRUG | a single dose of 150 mg PF-04991532, fasted |
| PF-04991532 + cyclosporine | DRUG | a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted |
Inclusion Criteria: * Healthy male and/or female (non-childbearing potential) subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse r...
PF-04991532 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers for a drug interaction trial.
PF-04991532 is being studied in healthy volunteers. The completed Phase 1 trial evaluated its pharmacokinetics when given with cyclosporine. The drug is not approved for any indication and remains in early clinical development.
PF-04991532 is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange.
PF-04991532 is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials currently listed for this drug.
PF-04991532 has one completed Phase 1 trial, NCT01370343, which studied the effect of cyclosporine on the pharmacokinetics of PF-04991532 in healthy volunteers. The trial enrolled 12 participants in Belgium.
PF-04991532 is not FDA approved. It is an investigational drug that has completed a Phase 1 trial in healthy volunteers, but it remains in clinical development and has not been approved for any use.